Biotech market research is the work of showing, with evidence, that a specific customer will pay for your science. It combines market sizing (how much revenue is on the table), industry analysis (whether you can realistically reach it) and primary conversations with the people who would buy, prescribe or license the product. Done early, it shapes your licensing, spinout and funding decisions. Done late, it only decorates a pitch deck.
This guide is written for university researchers, technology transfer teams and founders who hold a promising innovation and need to know what the market says about it. It covers what the work involves, how to size a market without fooling yourself, where U.S. data lives, and how the results should change what you do next.
TL;DR
- Market research for a biotech innovation answers three things: how big the opportunity is, who the customers and competitors are, and whether regulation, reimbursement and adoption let you capture a share.
- Use top-down and bottom-up sizing together, and treat the share you can realistically obtain as the number that matters, not the headline market size.
- Free, credible U.S. inputs exist: federal data, professional societies, academic publications and, for eligible SBIR/STTR awardees, the NIH Niche Assessment Program.
- Published forecasts for "the biotech market" vary enormously because the sector has no single definition. Read the scope behind every number.
- Your findings should drive a concrete decision: license, form a spinout, redirect development or change the go-to-market plan.
Table of Contents
- What biotech market research actually involves
- Sizing the market: TAM, SAM and SOM
- How large is the U.S. biotech market, and why do figures differ?
- Questions to answer before you commercialize
- Where to find U.S. data and which method fits your stage
- Reading forecasts with a critical eye
- From findings to decisions
- Our perspective
- How we can help
- FAQ
- Sources
What biotech market research actually involves
The NIH-supported Catalyze program describes market analysis as gathering data on a product's potential market and its existing competitors, then using that data to define the value proposition. In practice that breaks into four strands.
Customer needs. Who has the problem your technology solves? In biotech the customer is rarely one person. A diagnostic may have a patient, an ordering physician, a lab director and a payer, each with a different view of value.
Competing options. Competitors include other technologies, the current standard of care and the option of doing nothing. A reviewer will ask how your solution compares with what already exists, so the comparison has to be specific.
Market size. The total revenue opportunity and the portion you could actually win, covered in detail below.
Industry context. Regulatory pathway, supply chain, economics of the buyer and the speed of adoption. Utah State University's market research and commercialization guide draws a useful line here: quantifying market size tells you how large the opportunity is, while industry analysis tells you whether it is achievable. A big number with a closed door is not a market.
The same guide recommends using more than one analytical framework, for example SWOT, PESTLE and Porter's Five Forces, because each one exposes something the others miss. SWOT is good for an honest inventory of your own position, PESTLE catches political, legal and economic forces, and Five Forces shows how much pricing power buyers and suppliers hold.
Sizing the market: TAM, SAM and SOM
Investors, licensees and grant reviewers all expect the same three layers. The NHLBI's market sizing presentation defines them this way:
| Layer | What it means | Typical biotech question |
|---|---|---|
| TAM (Total Available Market) | The total revenue opportunity if everyone who could use the product did | How many patients have the condition, and what is spent on them today? |
| SAM (Serviceable Available Market) | The portion reachable given external factors such as geography, regulation and access | How many of those patients fit the labeled indication and are treated in settings we can serve? |
| SOM (Serviceable Obtainable Market) | The share of the SAM a company can realistically capture | What can we win in the first five years against entrenched competitors? |
Top-down versus bottom-up
Top-down sizing starts with broad available data and narrows toward your niche. You might start with national prevalence of a disease, then filter by stage, line of therapy and treatment setting. Bottom-up sizing starts with a small, specific segment and estimates how far it scales: the number of academic labs that would buy an instrument, multiplied by a realistic annual spend.
The NHLBI advises using both. Top-down gives you the breadth of industry reports, and bottom-up gives you the granular reality of primary data from potential customers. When the two numbers disagree, that gap is information. It usually means one set of assumptions is wrong.
The error that sinks most estimates
The same NHLBI material calls market sizing an art, not a science, and warns that overestimating the SOM is a common and critical mistake. Markets are not static, and estimates depend on assumptions and data quality. "One percent of a billion-dollar market" is not a plan. Name the customers who would adopt first, the sales channel that reaches them and the reason they would switch.
A worked example
Suppose a university lab has a point-of-care test for a condition affecting a defined U.S. patient group. A top-down pass takes prevalence data, removes patients already managed with a competing lab test, and keeps those seen in clinics that run point-of-care testing. That yields your SAM. A bottom-up pass interviews 20 clinic directors, learns how many tests each would order per month and at what price, then scales by the number of comparable clinics. If the bottom-up result is a fraction of the top-down one, you have learned that adoption, not disease prevalence, is the constraint. The SOM comes from the lower number, tempered by how many clinics you could realistically contact and convert.
How large is the U.S. biotech market, and why do figures differ?
A quick search shows the problem. Published global forecasts for biotechnology vary by multiples, from several hundred billion dollars to well over a trillion for similar years, because each publisher decides differently what counts as biotechnology. Treat any single headline figure as a statement about that publisher's scope.
The U.S. case is similar. TEConomy Partners' 2026 bioscience economy report for BIO found that the U.S. bioscience industry represented 2.31 million employees and $3.19 trillion in total economic output impacts in 2025. The report also notes that there is no single federal classification for the sector, so analysts must combine multiple industries across research, manufacturing and distribution. That is output impact, including ripple effects, not the revenue pool for your product.
The practical lesson: do not cite an industry-wide number as your market. Use it, at most, for context. Your TAM should be built from the specific disease, procedure, instrument category or workflow your technology touches.
Questions to answer before you commercialize
Catalyze lists the considerations researchers should work through: customer needs, how the solution compares with existing offerings, the potential market, competitors, the value proposition, and relevant stakeholders and market data. Turned into a working checklist for a biotech or medical technology:
- Who is the economic buyer? The user, the prescriber and the payer may be three different people.
- What is the current alternative, and what does it cost? Your price ceiling is set by what the buyer pays today.
- What evidence will the buyer require? Clinical data, analytical validation or real-world performance each take different time and money.
- What is the regulatory route? The pathway determines timeline and cost, and it shapes how much capital a startup needs. Our overview of FDA regulatory consulting covers what that support includes.
- How does the product get paid for? Formulary access, coverage and the relationships between payers, physicians and institutions all affect uptake.
- Which segment adopts first? Early adopters are often academic medical centers or specialty clinics, not the whole market.
- What does the intellectual property position allow? Freedom to operate and patent scope determine whether a license or a startup can defend a market.
Segmentation matters more than many teams expect. In a 2026 commercialization paper, McKesson argues that understanding patient demographics and social determinants of health, including factors such as race, wealth and language, is critical for segmenting the market and tailoring U.S. sales strategy. For therapeutics and diagnostics alike, who the patients are shapes where and how you reach them.
Where to find U.S. data and which method fits your stage
Sources worth starting with
The NHLBI's sizing guidance points U.S. researchers to government sources such as the CDC, industry reports, academic publications, professional societies and healthcare organizations. Each has a role:
- Federal health data for prevalence, incidence and utilization.
- Peer-reviewed literature for treatment patterns and unmet need.
- Professional society guidelines to see what clinicians consider standard of care and what would change their practice.
- Primary interviews with prospective customers, which no report can replace. Ask what they use now, what it costs them and what would make them switch.
A free option for SBIR and STTR awardees
If you hold a Phase I SBIR or STTR award from NIH, ask about the NIH Niche Assessment Program. It provides awardees with third-party, unbiased reports on end-user needs, competitive landscapes, market drivers and entry strategies. Check the NIH site for current eligibility and availability, since program details can change.
Matching the model to your stage
McKesson's guidance is that early-stage efforts typically use top-down models built on disease prevalence, while late-stage Phase 3 commercial teams should switch to bottom-up, physician-level prescribing data to predict market penetration. The same paper stresses that data must be timely and specific, especially in fast-moving fields like oncology, and that forecasts must account for formulary access and payer-physician-institution affiliations.
For a university spinout at the preclinical or early clinical stage, that translates into a simple rule. Use prevalence-driven top-down numbers to decide whether the problem is big enough to pursue, then spend your limited time on bottom-up interviews that test whether anyone would actually adopt.
Reading forecasts with a critical eye
Market reports are useful and also easy to misuse. Before you quote a forecast in a licensing pitch or grant application, run it through five checks:
- Scope. Does the definition match your product, or does it include agricultural, industrial and therapeutic biotech together?
- Geography. Is it global, North American or U.S.? Mixing them is a common slip.
- Method. Does the publisher explain whether it used top-down or bottom-up logic, and what assumptions drive the growth rate?
- Date. A figure from several years ago may predate major shifts in funding, regulation or technology.
- Obtainable share. Does the report say anything about what a new entrant could win? Usually it does not.
Regulation is a moving part too. BioUtah's life sciences industry overview observes that AI is accelerating drug discovery while also introducing new regulatory hurdles, so firms must balance rapid development against evolving federal oversight. A forecast that assumes today's rules will hold may be optimistic or pessimistic depending on where oversight goes.
From findings to decisions
Research only pays off when it changes what you do. Here is how typical findings map to the choices a research team faces.
Licensing or startup? If the market is concentrated in a few large buyers with established channels, and your technology fits their pipeline, licensing to an established company is often the faster route. If the market is fragmented, needs a new category or requires you to control development to preserve value, a spinout may fit better. A thin SOM may support neither, and that is a valuable thing to learn before spending patent budget.
Where to spend on IP. Market research shows which geographies and applications matter. That informs which claims to prioritize and where to file, rather than patenting everywhere by default.
Product development. Customer interviews often reveal that the feature you consider central is secondary, while a workflow detail drives purchase. Redirect development before it gets expensive.
Funding strategy. A large, well-defined unmet need supports venture conversations. A smaller specialized niche may be better served by non-dilutive funding such as SBIR/STTR grants, which reward a clear commercialization plan.
Go-to-market. Your first-adopter segment and the economic buyer define the sales motion, the evidence you must generate and the partners you need. They also define which investors and industry contacts are worth your time.
Our perspective
Most of the market research we see from research teams fails in the same place: it stops at a large top-down number and never reaches a customer. A TAM built from a trillion-dollar industry statistic tells a licensee nothing. What persuades is a defined first segment, a named economic buyer and an honest account of what stands between your technology and adoption.
Our team has worked inside major university technology transfer offices, in startup leadership, in federal grant review and in industry commercialization. That mix matters because each of those readers evaluates your market story differently. A licensing officer asks whether a company will take the risk. A grant reviewer asks whether the commercial plan is credible. An investor asks how large the obtainable share becomes. We build the analysis so it holds up for all three.
We treat market assessment as the first step of the commercialization path, not a separate report. The findings feed straight into patent strategy, licensing terms, spinout structure, funding choices and introductions to investors and industry. When the evidence says a technology is not ready, we say so early, because redirecting a project in month two costs far less than in year two.
the author
How we can help
If you hold a technology and need an outside view of its commercial potential, we support universities, researchers, founders and companies with market assessments, technology scouting and screening summaries, licensing support, funding strategy including SBIR/STTR, and go-to-market planning with investor and industry introductions. Our work is concentrated in life sciences, medical devices and engineering, and legal matters are coordinated with a dedicated IP law partner.
See the full range on our consulting services page, or start from the Tech Transfer Advisors home page to tell us about your technology.
FAQ
What is the difference between market research and market analysis for a biotech?
In commercialization the terms overlap. Research is the gathering: reports, public data and customer interviews. Analysis is the interpretation: sizing the opportunity, mapping competitors and judging whether the market is reachable. Most teams need both, in that order.
Should I use top-down or bottom-up market sizing?
Use both. The NHLBI recommends combining them so you get the breadth of industry data and the realism of primary data. Early on, top-down prevalence models help you decide whether to proceed, and bottom-up customer interviews then test whether the market will adopt.
Can I trust the market size figures published in industry reports?
Trust them only as far as you understand their scope. Reports define biotechnology differently, so global figures can differ by multiples. Check the definition, geography, date and method, and build your own TAM, SAM and SOM from your specific indication or product category.
Is there free help with market assessment for NIH-funded projects?
Phase I SBIR and STTR awardees can ask about the NIH Niche Assessment Program, which provides third-party reports on end-user needs, competitive landscape, market drivers and entry strategies. Confirm current eligibility on the NIH website, since programs change.
When in the research process should I start market research?
As soon as you have a credible result and a possible application, ideally before you file broad patent claims or apply for commercialization funding. Early findings can change which applications you pursue and where you spend your IP budget.
Sources
- Catalyze: Market Analysis
- NHLBI Catalyze: The Art of Market Sizing
- Utah State University: Market Research and Commercialization Guide
- TEConomy Partners for BIO: U.S. Bioscience Economy Report
- McKesson: Upgrade Your Commercialization Strategy with the Right Data
- NIH Notice NOT-OD-16-013: Niche Assessment Program
- BioUtah: Life Sciences overview